PA-824 (Q81294061)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18486052 AND SRC:MED&resulttype=core&format=json

7 January 2020

review article

1 reference

title

PA-824 (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18486052 AND SRC:MED&resulttype=core&format=json

7 January 2020

publication date

1 March 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18486052 AND SRC:MED&resulttype=core&format=json

7 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18486052 AND SRC:MED&resulttype=core&format=json

7 January 2020

volume

88

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18486052 AND SRC:MED&resulttype=core&format=json

7 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18486052 AND SRC:MED&resulttype=core&format=json

7 January 2020

page(s)

134-136

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18486052 AND SRC:MED&resulttype=core&format=json

A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis

7 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016/S1472-9792(08)70018-0

7 January 2021

Mycobacterium bovis BCG recA deletion mutant shows increased susceptibility to DNA-damaging agents but wild-type survival in a mouse infection model.

1 reference

https://api.crossref.org/works/10.1016/S1472-9792(08)70018-0

7 January 2021

Why metronidazole is active against both bacteria and parasites

1 reference

https://api.crossref.org/works/10.1016/S1472-9792(08)70018-0

7 January 2021

Nitroimidazole drugs-action and resistance mechanisms I. Mechanism of action

1 reference

https://api.crossref.org/works/10.1016/S1472-9792(08)70018-0

7 January 2021

Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016/S1472-9792(08)70018-0

7 January 2021

In vitro and in vivo activities of the nitroimidazole CGI 17341 against Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016/S1472-9792(08)70018-0

7 January 2021

In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans.

1 reference

https://api.crossref.org/works/10.1016/S1472-9792(08)70018-0

7 January 2021

Mycobacterium leprae is naturally resistant to PA-824

1 reference

https://api.crossref.org/works/10.1016/S1472-9792(08)70018-0

7 January 2021

Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models

1 reference

https://api.crossref.org/works/10.1016/S1472-9792(08)70018-0

7 January 2021

Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis

1 reference

https://api.crossref.org/works/10.1016/S1472-9792(08)70018-0

7 January 2021

Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis

1 reference

https://api.crossref.org/works/10.1016/S1472-9792(08)70018-0

7 January 2021

10.1016/S1472-9792(08)70018-0

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18486052 AND SRC:MED&resulttype=core&format=json

7 January 2020

1 reference